ENDRA Life Sciences Inc (NASDAQ: NDRA)’s stock price has gone decline by -2.36% in comparison to its previous close of $3.54, however, the company has experienced a -3.45% decrease in its stock price over the last five trading days. businesswire.com reported 2025-06-16 that ANN ARBOR, Mich.–(BUSINESS WIRE)–ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer in imaging technologies for the early detection and monitoring of metabolic liver disease, today announced that its ongoing multisite pilot study has helped to identify several product enhancements to further improve the performance of its TAEUS® Liver system against the gold standard, MRI. These findings are expected to drive substantial improvements to the device’s probe design and proprietary algorithms, me.
Is It Worth Investing in ENDRA Life Sciences Inc (NASDAQ: NDRA) Right Now?
Moreover, the 36-month beta value for NDRA is -0.21. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy”, 0 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for NDRA is 0.74M and currently, short sellers hold a 2.29% of that float. On July 08, 2025, NDRA’s average trading volume was 179.16K shares.
NDRA’s Market Performance
NDRA stock saw a decrease of -3.45% in the past week, with a monthly decline of -2.90% and a quarterly a decrease of -12.49%. The volatility ratio for the week is 7.44%, and the volatility levels for the last 30 days are 6.53% for ENDRA Life Sciences Inc (NDRA). The simple moving average for the last 20 days is 0.57% for NDRA’s stock, with a simple moving average of -33.77% for the last 200 days.
NDRA Trading at -10.16% from the 50-Day Moving Average
After a stumble in the market that brought NDRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.97% of loss for the given period.
Volatility was left at 6.53%, however, over the last 30 days, the volatility rate increased by 7.44%, as shares surge +2.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.56% lower at present.
During the last 5 trading sessions, NDRA fell by -3.45%, which changed the moving average for the period of 200-days by -55.11% in comparison to the 20-day moving average, which settled at $3.44. In addition, ENDRA Life Sciences Inc saw -97.79% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NDRA starting from UBS Group AG, who purchase 3,715 shares at the price of $0.55 back on Aug 27 ’24. After this action, UBS Group AG now owns 146,012 shares of ENDRA Life Sciences Inc, valued at $2,052 using the latest closing price.
N/A, the N/A of ENDRA Life Sciences Inc, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for NDRA
Current profitability levels for the company are sitting at:
- -37.98% for the present operating margin
- 0.26% for the gross margin
The net margin for ENDRA Life Sciences Inc stands at -46.17%. The total capital return value is set at -3.09%. Equity return is now at value -358.41%, with -237.35% for asset returns.
Based on ENDRA Life Sciences Inc (NDRA), the company’s capital structure generated 0.25 points at debt to capital in total, while cash flow to debt ratio is standing at -11.15.
Currently, EBITDA for the company is -11.3 million with net debt to EBITDA at 0.19. When we switch over and look at the enterprise to sales, we see a ratio of 5.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.85.
Conclusion
To wrap up, the performance of ENDRA Life Sciences Inc (NDRA) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
